Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference
January 03 2018 - 4:05PM
YASTEST
DUBLIN, Ireland,
Jan. 3, 2018 - Prothena Corporation plc (NASDAQ:PRTA), a
late-stage clinical biotechnology company focused on the discovery,
development and commercialization of novel therapies in the
neuroscience and orphan categories, today announced that members of
its senior management team will present and participate in the 36th
Annual J.P. Morgan Healthcare Conference on January 10th at 8:30 AM
PT in San Francisco, CA.
A live webcast of the company
presentation can be accessed through the Investors section of the
Company's website at www.prothena.com. Following the live
presentation, a replay of the webcast will be available on the
Company's website for at least 90 days following the presentation
date.
About
Prothena
Prothena Corporation plc is a
global, late-stage clinical biotechnology company establishing
fully integrated research, development and commercial capabilities
and focused on advancing new therapies in the neuroscience and
orphan categories. Fueled by its deep scientific understanding
built over decades of research in protein misfolding, Prothena
seeks to fundamentally change the course of grave or currently
untreatable diseases associated with this biology. Prothena's
pipeline of antibody therapeutic candidates targets a number of
indications including AL amyloidosis (NEOD001), Parkinson's disease
and other related synucleinopathies (PRX002/RG7935) and ATTR
amyloidosis (PRX004). The Company continues discovery of additional
novel therapeutic candidates where its deep scientific
understanding of disease pathology can be leveraged. For more
information, please visit the Company's website at
www.prothena.com.
Media &
Investor Contact:
Ellen Rose, Head of
Communications
650-922-2405,
ellen.rose@prothena.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Prothena Corporation plc via Globenewswire
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Apr 2023 to Apr 2024